SanBio (サンバイオ株式会社) is a biotech company engaged in the development of regenerative medicine. It offers SB623, a cell-based investigational product made from modified and cultured adult bone marrow-derived mesenchymal stem cells that undergo temporary genetic modification. Implantation of SB623 cells into injured nerve tissue in the brain is expected to trigger the brain's natural regenerative ability to recover lost motor functions.